NurExone Announces Promising Preclinical Results in Restoring Vision After Optic Nerve Damage
December 06, 2024 16:03 ET
|
NurExone Biologic Inc
NurExone announces significant findings from a preclinical study of the potential of its portfolio drug, ExoPTEN, for repairing Optic Nerve Damage (OND)
NurExone Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 27, 2024 07:01 ET
|
NurExone Biologic Inc
NurExone Reports Third Quarter 2024 Financial Results
and Provides Corporate Update
Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA
October 08, 2024 07:00 ET
|
Teva Pharmaceutical Industries Ltd
Prolia® (denosumab) is indicated to treat certain conditions that lead to high risk for fracture, including osteoporosis in postmenopausal womenTVB-009P, Teva’s proposed biosimilar to Prolia, showed...
ExCellThera Announces EMA’s Acceptance under Accelerated Assessment of Market Authorisation Application (MAA) for UM171 Cell Therapy for Patients with Hematological Malignancies who Lack a Readily Available Suitable Donor
June 25, 2024 07:00 ET
|
ExCellThera
Market Authorisation Application (MAA) for ExCellThera's UM171 Cell Therapy accepted under accelerated assessment by the European Medicines Agency
Triple Hair Group reçoit l'approbation de l'EMA pour commencer les essais cliniques de phase III sur son médicament sur ordonnance Thérapie-07 en Europe
June 19, 2024 07:30 ET
|
Triple Hair Inc.
MONTRÉAL, 19 juin 2024 (GLOBE NEWSWIRE) -- Triple Hair Group Inc. (« Triple Hair » ou la « Société »), une société spécialisée dans le développement de traitements novateurs contre l'alopécie...
Triple Hair Group Receives EMA Approval to Start Phase III Clinical Trials on its Therapy-07 Prescription Drug in Europe
June 19, 2024 07:30 ET
|
Triple Hair Inc.
MONTRÉAL, June 19, 2024 (GLOBE NEWSWIRE) -- Triple Hair Group Inc. (“Triple Hair” or the “Company”), a company specializing in the development of innovative treatments for androgenic alopecia,...
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
April 24, 2024 07:05 ET
|
Travere Therapeutics, Inc.
Travere and CSL Vifor announce EC approval of FILSPARI (sparsentan) for treatment of IgAN, 1st non-immunosuppressive treatment for IgAN approved in Europe
Waiting for new medicines in Canada, Europe, and the United States: Study finds Americans get better and faster access to innovative drugs
April 11, 2024 10:30 ET
|
Canadian Health Policy Institute Inc.
Americans get better and faster access to innovative medicines compared to Europeans and Canadians.
Access to new medicines in Canada, Europe, and the United States: Study finds less availability and longer waits for Canadian patients
April 11, 2024 10:00 ET
|
Canadian Health Policy Institute Inc.
A recent study published by the Canadian Health Policy Institute examined the availability and wait times for access to new drugs.
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
February 23, 2024 07:05 ET
|
Travere Therapeutics, Inc.
Committee for Medicinal Products for Human Use (CHMP) recommends approval of the conditional marketing authorization (CMA) for sparsentan for the treatment of IgA nephropathy (IgAN) in Europe ...